PMID- 36901724
OWN - NLM
STAT- MEDLINE
DCOM- 20230316
LR  - 20231215
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 5
DP  - 2023 Feb 21
TI  - Electronic Cigarette Exposure Increases the Severity of Influenza a Virus 
      Infection via TRAIL Dysregulation in Human Precision-Cut Lung Slices.
LID - 10.3390/ijms24054295 [doi]
LID - 4295
AB  - The use of electronic nicotine dispensing systems (ENDS), also known as 
      electronic cigarettes (ECs), is common among adolescents and young adults with 
      limited knowledge about the detrimental effects on lung health such as 
      respiratory viral infections and underlying mechanisms. Tumor necrosis factor 
      (TNF)-related apoptosis-inducing ligand (TRAIL), a protein of the TNF family 
      involved in cell apoptosis, is upregulated in COPD patients and during influenza 
      A virus (IAV) infections, but its role in viral infection during EC exposures 
      remains unclear. This study was aimed to investigate the effect of ECs on viral 
      infection and TRAIL release in a human lung precision-cut lung slices (PCLS) 
      model, and the role of TRAIL in regulating IAV infection. PCLS prepared from 
      lungs of nonsmoker healthy human donors were exposed to EC juice (E-juice) and 
      IAV for up to 3 days during which viral load, TRAIL, lactate dehydrogenase (LDH), 
      and TNF-alpha in the tissue and supernatants were determined. TRAIL neutralizing 
      antibody and recombinant TRAIL were utilized to determine the contribution of 
      TRAIL to viral infection during EC exposures. E-juice increased viral load, 
      TRAIL, TNF-alpha release and cytotoxicity in IAV-infected PCLS. TRAIL neutralizing 
      antibody increased tissue viral load but reduced viral release into supernatants. 
      Conversely, recombinant TRAIL decreased tissue viral load but increased viral 
      release into supernatants. Further, recombinant TRAIL enhanced the expression of 
      interferon-beta and interferon-lambda induced by E-juice exposure in IAV-infected PCLS. 
      Our results suggest that EC exposure in human distal lungs amplifies viral 
      infection and TRAIL release, and that TRAIL may serve as a mechanism to regulate 
      viral infection. Appropriate levels of TRAIL may be important to control IAV 
      infection in EC users.
FAU - Agraval, Hina
AU  - Agraval H
AD  - Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 
      80206, USA.
FAU - Crue, Taylor
AU  - Crue T
AUID- ORCID: 0000-0002-8469-9546
AD  - School of Medicine, University of Colorado, 12700 E 19th Ave, Aurora, CO 80045, 
      USA.
FAU - Schaunaman, Niccolette
AU  - Schaunaman N
AD  - Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 
      80206, USA.
FAU - Numata, Mari
AU  - Numata M
AD  - Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 
      80206, USA.
FAU - Day, Brian J
AU  - Day BJ
AD  - Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 
      80206, USA.
FAU - Chu, Hong Wei
AU  - Chu HW
AD  - Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 
      80206, USA.
LA  - eng
GR  - R01 HL144396/HL/NHLBI NIH HHS/United States
GR  - R01 HL144396/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20230221
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (TNFSF10 protein, human)
SB  - IM
MH  - Adolescent
MH  - Humans
MH  - Young Adult
MH  - Antibodies, Neutralizing/metabolism
MH  - *Electronic Nicotine Delivery Systems
MH  - *Influenza A virus/physiology
MH  - *Influenza, Human
MH  - Lung/pathology
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC10002047
OTO - NOTNLM
OT  - Influenza A virus
OT  - PCLS
OT  - TRAIL
OT  - electronic cigarettes
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/12 06:00
MHDA- 2023/03/15 06:00
PMCR- 2023/02/21
CRDT- 2023/03/11 01:15
PHST- 2023/01/25 00:00 [received]
PHST- 2023/02/09 00:00 [revised]
PHST- 2023/02/19 00:00 [accepted]
PHST- 2023/03/11 01:15 [entrez]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/02/21 00:00 [pmc-release]
AID - ijms24054295 [pii]
AID - ijms-24-04295 [pii]
AID - 10.3390/ijms24054295 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Feb 21;24(5):4295. doi: 10.3390/ijms24054295.